- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00377403
Treatment of Acute Sinusitis
Randomized Clinical Trial to Evaluate Guidelines for Acute Rhinosinusitis (Phase IV Study)
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Missouri
-
St. Louis, Missouri, United States, 63110
- Washington University in St. Louis
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The subject must be male or female, and between the ages of 18 and 70 years old.
- The subject must have symptoms of acute bacterial rhinosinusitis.
- The subject must be attending a participating primary care practice in the community.
- The subject must have symptoms of acute bacterial rhinosinusitis self-assessed as moderate, severe, or very severe.
- The subject must have access to a phone.
Exclusion Criteria:
- The subject is less than 18 years old or more than 70 years old.
- The subject has very mild or mild symptom severity assessed by self report.
- The subject has an allergy to penicillin or amoxicillin.
- The subject has received antibiotic therapy within the past 4 weeks (including chronic treatment for acne and low dose prophylactic treatment).
- The subject has complications of sinusitis (facial edema, cellulitis, or orbital, meningeal or cerebral signs).
- The subject is thought to require intravenous antibiotics or hospital admission.
- The subject is pregnant. (This will be assessed by self-report. A pregnancy test will not be required).
- The subject has a comorbidity that may impair their immune response (such as immunodeficiency disease, uncontrolled cancer, or chemotherapy or radiation treatment).
- The subject has cystic fibrosis.
- The subject has Type I diabetes or is taking insulin to treat diabetes.
- The subject had prior sinus surgery.
- The subject requires an antibiotic for a concurrent condition such as an ear infection.
- The subject is not able to complete the study protocol because of language barriers, lack of telephone access, or other issues.
- Any other condition that the provider feels may interfere with the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention Arm
Amoxicillin 500mg three times a day (tid) for 10 days in addition to symptomatic treatments
|
Symptomatic treatment: Dose: 500mg every 4 to 6 hours for pain or fever
Other Names:
Intervention drug: Dose: 500mg tid for 10 days
Other Names:
Symptomatic treatment: Dose: 10mls every 4 to 6 hours for cough
Other Names:
Symptomatic treatment: Dose: 600mg every 12 hours to thin secretions
Other Names:
Symptomatic treatment: Dose: 120mg every 12 hours for nasal congestion
Other Names:
Symptomatic treatment: Dose: 2 squeezes per nostril as needed for nasal congestion
Other Names:
|
Placebo Comparator: Symptomatic treatments only
Placebo for 10 days in addition to symptomatic treatments
|
Symptomatic treatment: Dose: 500mg every 4 to 6 hours for pain or fever
Other Names:
Symptomatic treatment: Dose: 10mls every 4 to 6 hours for cough
Other Names:
Symptomatic treatment: Dose: 600mg every 12 hours to thin secretions
Other Names:
Symptomatic treatment: Dose: 120mg every 12 hours for nasal congestion
Other Names:
Symptomatic treatment: Dose: 2 squeezes per nostril as needed for nasal congestion
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
SNOT-16 Score (Sino-Nasal Outcomes Test) at Day 3
Time Frame: 4 days
|
The Sino-Nasal Outcomes Test (SNOT-16) assesses disease-specific quality of life for acute and chronic rhinosinusitis.
This brief instrument assesses 16 sinus-related symptoms and was administered by phone.
The respondent reported how much they were bothered by each item considering both its severity and frequency.
Response options include no problem (0), mild or slight problem (1), moderate problem (2), severe problem (3).
The SNOT-16 score is the mean score from all 16 items and ranges from 0 (minimal impact) to 3 (significant impact).
|
4 days
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Garbutt JM, Banister C, Spitznagel E, Piccirillo JF. Amoxicillin for acute rhinosinusitis: a randomized controlled trial. JAMA. 2012 Feb 15;307(7):685-92. doi: 10.1001/jama.2012.138.
- Garbutt J, Spitznagel E, Piccirillo J. Use of the modified SNOT-16 in primary care patients with clinically diagnosed acute rhinosinusitis. Arch Otolaryngol Head Neck Surg. 2011 Aug;137(8):792-7. doi: 10.1001/archoto.2011.120.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Respiratory Tract Diseases
- Respiratory Tract Infections
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Excitatory Amino Acid Antagonists
- Excitatory Amino Acid Agents
- Analgesics, Non-Narcotic
- Antipyretics
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Anti-Bacterial Agents
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Appetite Depressants
- Anti-Obesity Agents
- Central Nervous System Stimulants
- Antitussive Agents
- Sympathomimetics
- Expectorants
- Vasoconstrictor Agents
- Nasal Decongestants
- Acetaminophen
- Dextromethorphan
- Amoxicillin
- Ephedrine
- Pseudoephedrine
- Phenylpropanolamine
- Guaifenesin
- Chlorpheniramine, phenylpropanolamine drug combination
Other Study ID Numbers
- 05-0140
- U01AI064655-01A1 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Respiratory Infections
-
Hôpital Universitaire SahloulCompleted
-
Wits Health Consortium (Pty) LtdFred Hutchinson Cancer Center; Janssen Vaccines & Prevention B.V.; National Institute... and other collaboratorsCompletedSARS (Severe Acute Respiratory Syndrome)South Africa
-
University of SaskatchewanGovernment of Canada; Vaccine Formulation Institute (VFI); Government of Saskatchewan and other collaboratorsCompletedSevere Acute Respiratory Syndrome Coronavirus 2Canada
-
Pulmoquine Therapeutics, IncRockefeller UniversityCompletedSevere Acute Respiratory Syndrome Coronavirus 2United States
-
University of Cape TownUniversity of KwaZuluUnknownSevere Acute Respiratory Syndrome Coronavirus 2South Africa
-
University Hospital, Strasbourg, FranceCompletedSARS (Severe Acute Respiratory Syndrome)France
-
University of SaskatchewanGovernment of Canada; Vaccine Formulation Institute (VFI); Government of Saskatchewan and other collaboratorsCompleted
-
University of SaskatchewanGovernment of Canada; Government of SaskatchewanWithdrawnSevere Acute Respiratory Syndrome Coronavirus 2
-
University of WashingtonJohns Hopkins University; National Institute of Diabetes and Digestive and... and other collaboratorsActive, not recruitingCovid19 | Acute Renal Failure | Acute Renal Injury | Acute Kidney Failure | Kidney Failure, Acute | Renal Insufficiency, Acute | Acute Renal Insufficiency | Sars-CoV-2 Infection | Acute Kidney Insufficiency | Renal Failure, Acute | Kidney Insufficiency, AcuteUnited States
-
ANRS, Emerging Infectious DiseasesRecruitingSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)France, Martinique
Clinical Trials on Acetaminophen
-
Massachusetts General HospitalCompletedPain, Postoperative | Infertility, FemaleUnited States
-
Kaveh Aslani, MDCompletedAirway Obstruction | Tonsillitis | Difficulty SwallowingUnited States
-
Taipei Medical University WanFang HospitalUnknownCervical Radiculopathy | Radicular Pain | Acute Neck Pain | Cervicobrachial PainTaiwan
-
Medical University of South CarolinaCompletedPain, PostoperativeUnited States
-
MallinckrodtTerminatedAcute Pain, PostoperativeUnited States
-
Duke UniversityCompletedOsteoarthritis | Acetaminophen | Arthroplasty, Hip ReplacementUnited States
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruiting
-
Spectrum Health HospitalsTerminatedHip FractureUnited States
-
Babiash, Kimberly H., M.D.Unknown
-
Beth Israel Deaconess Medical CenterNational Center for Research Resources (NCRR); Harvard UniversityCompletedAcetaminophen Poisoning | Acetaminophen Metabolism | Drug Metabolism by ExcipientsUnited States